PBM/Manufacturer Therapeutic Substitution Contracts Sought In FTC Study
Executive Summary
The Federal Trade Commission is asking pharmacy benefit management companies to submit their "therapeutic substitution" contracts with pharmaceutical manufacturers as part of a study of "conflicts of interest" in the PBM sector
You may also be interested in...
PBM Disclosure Requirements On Rx Switches Likely To Increase Costs – FTC
Pharmaceutical benefit manager disclosure requirements related to drug switches are likely to increase consumers' drug costs rather than strengthen consumer protections, the Federal Trade Commission said in its review of PBM transparency legislation under consideration in California
PBM Disclosure Requirements On Rx Switches Likely To Increase Costs – FTC
Pharmaceutical benefit manager disclosure requirements related to drug switches are likely to increase consumers' drug costs rather than strengthen consumer protections, the Federal Trade Commission said in its review of PBM transparency legislation under consideration in California
PBM “Transparency” Defined In Medco Settlement
The Medco injunction requires the pharmacy benefit management company to disclose the existence of rebate relationships in its communications to clients, physicians and patients